Follow clinical progress, product pipelines, commercialization and industry performance.
Brukinsa’s global sales growth drove BeOne’s third-quarter product revenue above Goldman Sachs’ expectations, while slower expense growth than revenue growth amplified profit growth. The company raised its full-year guidance again, while Goldman Sachs also focused on R&D spending associated with the expansion of its drug pipeline.
The company reaffirmed its full-year 2027 profitability target and plans to significantly reduce R&D expenses; however, Crysvita sales in the third quarter were below market expectations, and the rollout of two gene therapies will affect future growth.
AVLAYAH’s third-quarter sales reached 17.8 million dollars, and fourth-quarter guidance also exceeded expectations. Expanded insurance coverage and clinical-trial patients switching to commercial drug use drove growth, but management expects the growth rate to stabilize thereafter.
JPMorgan expects Dupixent sales to exceed 25 billion euros in 2028, two years ahead of the medium-term target; however, asset sales will weigh on revenue growth in 2027, while pipeline progress remains a factor in valuation assessments.
Bernstein expects demand for chronic-disease and specialty medicines to drive expansion of India’s domestic biopharmaceutical market. In initiating coverage of three listed multinational pharmaceutical companies in India, it names GSK India its top pick; Pfizer first needs to offset the exit of mature products, while Abbott faces a lack of new products and brand competition.
Domestic surgical robot sales grew 17% in 2025; BOCI International believes technological advances and pricing policies could help products penetrate more tiers of hospitals.
Product sales rose 33% year on year in the third quarter of 2026, driving RemeGen to a second consecutive quarter of recurring profitability. J.P. Morgan is positive on the full-year product sales and break-even targets but has lowered its 2027 revenue forecast and its A- and H-share price targets.
Six preclinical assets are included in the partnership. Boehringer Ingelheim has options to acquire global rights to two and rights outside Greater China to the other four. Nomura expects the near-term payments to significantly benefit Sinobiopharma’s results for fiscal years 2026 and 2027.
Waters delivered 10% organic revenue growth in the third quarter and raised its full-year guidance. Bernstein believes improving business in China, acquisition synergies and orders tied to pharmaceutical manufacturing returning to the US leave room for upside to the company’s cautious 2027 framework.
Life sciences drove Revvity's third-quarter organic growth and margin above market consensus, and the company raised its full-year guidance. Bernstein says AI demand's contribution is difficult to quantify separately and maintains its Market Perform rating on valuation grounds.
Amgen’s growth products offset some declines in older drugs, and the company raised its full-year revenue and earnings-per-share guidance; Bernstein believes one-time sales benefits and expense timing also boosted third-quarter performance.
Preliminary first-line lung cancer data for IBI363 support further study, but small samples leave median progression-free survival subject to fluctuations; management also expects a broader product portfolio to support sales growth in 2027.
Management lowered its forecast for domestic reagent price declines in 2027 and set a test-volume growth target of around 15%; however, industry demand remains weak, and the situation in the Middle East and exchange rates are also weighing on overseas operations.
Management reiterated confidence in product sales growth of approximately 35% in 2026 and is advancing its hematologic oncology and autoimmune pipelines. Goldman Sachs sees potential in differentiated R&D and global partnerships, but its model forecasts a decline in profit metrics in 2027.
Growth in existing innovative drugs and new product launches support Hansoh Pharma's near-term targets; the company plans to expand its marketed innovative drugs from 9 to 30 by 2030, with its ADC and metabolic disease pipelines as important sources.
Third-quarter revenue and net profit rose 27.2% and 41.8% year on year, respectively. HSBC Qianhai expects a lower expense ratio to offset some pricing pressure from volume-based procurement, but its overall revenue forecast remains broadly unchanged as growth in the peripheral vascular intervention business levels off.
Domestic medical equipment tenders returned to year-on-year growth in the third quarter of 2026, while company revenues improved. JPMorgan believes changes in procurement rules and lower geopolitical sensitivity are also supporting sector performance.
New CDMO purchase orders rose 40% year on year in the third quarter of 2026, and the revenue share of late-stage and commercial projects is expected to rise; capacity expansion and delivery of large orders will affect the realization of growth and margins.
Product sales rose 33% year over year in the third quarter of 2026, helping RemeGen achieve recurring profitability for a second consecutive quarter. J.P. Morgan is optimistic about new indications and overseas phase III trials, but has lowered its 2027 revenue forecast and price targets for the A and H shares.
Pfizer raised its 2026 guidance, and JPMorgan modestly increased its forecasts. However, the bank expects revenue and earnings per share to decline over the next two years, with data from most major pipeline programs due at the end of 2027 or later.
